Gilead may soon be bringing a new cocktail of HIV drugs to market. The company said Monday that a combination of two drugs achieved non-inferiority

Aviceda Therapeutics is pushing forward with Phase 3 plans for its experimental eye drug despite failing a Phase 2b study in geographic atrophy. The mid-stage

Palvella Therapeutics said its drug candidate for a rare skin disease that affects children has yielded positive results in a mid-stage trial. The biotech’s gel

InnoCare Pharma’s experimental oral BTK inhibitor, called orelabrutinib, succeeded in a mid-stage trial in systemic lupus erythematosus (SLE), the Chinese biotech said Sunday. After nearly

Kyverna Therapeutics’ CAR-T therapy succeeded in a key study in stiff person syndrome, a rare autoimmune disorder that leads to painful muscle spasms and stiffness.